Thursday, September 19, 2024

Marc ZERBOLA CHALLANDE

137 POSTS
Marc has been involved in the Stock Market Media Industry for the last +5 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Capital where he was head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including breaking news technology, metals & mining markets.

Exclusive articles:

Swarmio Media (SWRM.CN) partnered with Apelby

Swarmio Media (SWRM.CN), a gaming & technology company that provides products and services designed to help gamers make the most out of their hobby,...

Biolife Sciences has a solid Mfusion process.

BioLife Sciences (OTC: BLFE), a company that develops, licenses, and distributes antibacterial products and non-contact human temperature screening technology, witnessed recently, on December 2021,...

Atlas Salt, the Great Canadian Hydrogen Play

Atlas Salt is one of these great stories on the venture exchange. During these days, when most companies saw their valuations decreasing, SALT brought...

Fandifi Sees its Volume Increasing

Maybe you haven’t noticed it, but Fandifi (FMD.CN)’s volume has incredibly augmented on August 2, and it’s caught the eye of many investors. Indeed...

Pharmagreen Biotech Can Grow Big in the Short-Term

You might have ever heard that investing in pink sheets is risky for many reasons. The most famous one is because of limited information,...

Breaking

Investing in Biotech: Why 2024 Could Be the Year of Major Gains

2024 sees a biotech rebound, with over 15 IPOs...

Li-FT Power: Fueling the EV Future with Strategic Lithium Exploration

Li-FT Power Ltd. ("LIFT" or the "Company") (CSE: LIFT) (OTCQX:...

America’s Fight for Uranium Freedom: Will It Ever End?

The U.S. is actively working to reduce its reliance...

Bright Minds Targets Epilepsy with Breakthrough 5-HT2C Agonist

Bright Minds Biosciences launches a Phase 2 trial for...
spot_img